Welcome, Guest. Please login or register.
November 18, 2017, 03:58:29 AM

Login with username, password and session length

  • Total Members: 31843
  • Latest: conanyx
  • Total Posts: 722391
  • Total Topics: 58699
  • Online Today: 284
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 2
Guests: 240
Total: 242


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: JTT-705 for low cholesterol  (Read 1773 times)

0 Members and 1 Guest are viewing this topic.

Offline ZCorker

  • Member
  • Posts: 48
JTT-705 for low cholesterol
« on: February 16, 2009, 12:50:05 AM »
What ever happened to JTT-705?  This is drug is supposed raise HDL Cholesterol (good cholesterol).  The last I heard, Roche was looking for investigators and was asking Heart Doctors and Endocrinologist to sign up on Roche's website.

Has anyone heard what is going on with this?  Different than Pfizer, Roche has decided not exclude hiv patients from the study.  Clinicians interested in participating can sign up on the website can sign up at



Offline veritas

  • Member
  • Posts: 1,410
Re: JTT-705 for low cholesterol
« Reply #1 on: February 16, 2009, 03:55:02 PM »

Latest research I could find:


 INTRODUCTION: While elevated plasma HDL levels are inversely correlated with cardiovascular events, raising HDL with the CETP inhibitor torcetrapib, however, was associated with increased cardiovascular morbidity and mortality in the ILLUMINATE trial. Whether the deleterious clinical effects of torcetrapib represent a molecule specific off-target effect, a class effect of CETP inhibitors or both is matter of ongoing debate. As such, the aim of the present study was to investigate whether CETP-inhibition with JTT-705, a molecule distinctly different from torcetrapib, impacts on vascular function, a well-established surrogate of atherosclerotic vascular disease, as well as markers of inflammation and oxidative stress in patients with type II hyperlipidemia. METHODS AND RESULTS: Eighteen patients were randomized to receive JTT-705 600 mg/d or matching placebo for 4 weeks. Flow-mediated dilation (FMD) was measured using ultrasonography of the brachial artery. HDL-C increased by 26% from 1.14 mmol/l to 1.44 mmol/l (p=0.01) in the JTT-705 group, while triglycerides decreased from 2.52 mmol/l to 1.97 mmol/l (p=0.03). CETP- inhibition with JTT-705, however, did not change FMD (3.1+/-0.6% to 3.6+/-0.4%; p=0.48). Interestingly, in a sub group analysis of patients with lower than median HDL-C (<1.19 mmol/l), FMD increased by 41% in patients vs. patients with higher than median HDL-C (>1.19 mmol/l; p=0.01). Markers of vascular inflammation (CRP, ICAM-1, IL-6, TNF alpha), as well as plasma endothelin-1 levels all remained unchanged throughout the study. CONCLUSION: In patients with type II hyperlipidemia, CETP inhibition with JTT-705 increased HDL-C and lowered triglycerides but improved endothelial function in the subgroup of patients with low baseline HDL-C levels only.
Authors Frank Hermann, Frank Enseleit, Lukas E Spieker, Daniel Périat, Isabella Sudano, Matthias Hermann, Roberto Corti, Georg Noll, Frank Ruschitzka, Thomas F Lüscher
Journal Thrombosis research (Thromb Res) Vol. 123 Issue 3 Pg. 460-5 ( 2009) ISSN: 0049-3848 United States
PMID 18789492 (Publication Type: Journal Article) 



Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.